eTable 2.

Multivariable Analysis of Factors Associated with Neoadjuvant Endocrine Therapy Receipt

Patient characteristic	OR (95% CI)	p Value
Age
18–39 y	1	Ref
40–49 y	1.02 (0.73–1.41)	0.93
50–59 y	1.41 (1.02–1.93)	0.04
60–69 y	1.73 (1.26–2.38)	< 0.01
70–79 y	1.92 (1.38–2.66)	< 0.01
80+ y	2.63 (1.88–3.69)	< 0.01
Race
White	1	Ref
Black	1.06 (0.93–1.21)	0.38
Hispanic	1.35 (1.17–1.56)	< 0.01
Asian	1.07 (0.88–1.30)	0.50
Charlson Comorbidity Index
0	1	Ref
1	0.88 (0.79–0.97)	0.01
2	1.32 (1.10–1.59)	< 0.01
≥ 3	1.83 (1.41–2.39)	< 0.01
Insurance
Private	1	Ref
Medicare	1.16 (1.05–1.29)	< 0.01
Medicaid	1.47 (1.26–1.70)	< 0.01
Uninsured	1.53 (1.18–1.99)	< 0.01
Region
Metro	1	Ref
Urban	1.02 (0.91–1.13)	0.77
Rural	1.06 (0.81–1.39)	0.66
Unknown	1.17 (0.95–1.45)	0.15
Facility type
Community	1	Ref
Comprehensive	1.13 (0.97–1.30)	0.11
Academic	1.62 (1.40–1.87)	< 0.01
Integrated Network	1.59 (1.36–1.87)	< 0.01
Histology
Ductal	1	Ref
Lobular	1.17 (1.06–1.29)	< 0.01
Mixed	1.09 (0.98–1.22)	0.12
Grade
1	1	Ref
2	0.80 (0.74–0.87)	< 0.01
3	0.45 (0.40–0.51)	< 0.01
cT
cT1	1	Ref
cT2	5.40 (5.01–5.81)	<0.01

cT, clinical tumor category; OR, odds ratio; Ref, reference.